Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Mindray Medical International

Related MR
Stocks Hitting 52-Week Lows
Benzinga's Top Downgrades

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Mindray Medical International (NYSE: MR), and raised its price target from $34.00 to $36.00.

Jefferies noted, “MR put up a mixed 3Q with a drastic slowdown in PMLS, a sequential stepback in the margin profile, but in-line non-GAAP EPS. Language regarding deterioration in developed markets, abrupt CEO change, and still unresolved supplier dispute leave lingering questions but overall growth profile still among upper tier.”

Mindray Medical International closed on Tuesday at $31.90.

Latest Ratings for MR

Dec 2014Standpoint ResearchInitiates Coverage onBuy
Dec 2014Morgan StanleyDowngradesEqual-weightUnderweight
May 2014JefferiesAssumesHold

View More Analyst Ratings for MR
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (MR)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→